

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/259132 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 14/47 (2006.01)
A61K 51/08 (2006.01) A61K 38/00 (2006.01)
C07K 7/08 (2006.01)

(21) International Application Number:

PCT/US2024/033849

(22) International Filing Date:

13 June 2024 (13.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,202 14 June 2023 (14.06.2023) US
63/557,140 23 February 2024 (23.02.2024) US

(71) Applicant: **MARIANA ONCOLOGY INC.** [US/US];
100 Forge Road, Suite 600, Watertown, Massachusetts
02472 (US).

(72) Inventors: **METCALF III, Chester A.**; 70 Blake Street,
Needham, Massachusetts 02492 (US). **HUANG, Chun-
hui**; 157 Woodside Lane, Arlington, Massachusetts 02474
(US). **WAN, Murray**; 155 Sturges Street, Medford, Mass-
achusetts 02155 (US). **BRUTON, Thomas C.**; 404 Piscas-
sic Street, Newmarket, New Hampshire 03857 (US). **MA,
Zhong**; 2 Jonathan Lane, Bedford, Massachusetts 01730
(US). **WU, Lihua**; 48 Selwyn Rd., Belmont, Massachusetts
02478 (US). **COSTANTE, Roberto**; Via Padova 15, 00071
Pomezia (IT). **BRANCA, Danila**; Via Pietro Nenni 26B,
00071 Pomezia (IT). **RICARDO, Alonso**; 5 Wagon Wheel
Rd., Winchester, Massachusetts 01890 (US).

(74) Agent: **TRINQUE, Brian C.**; Lathrop GPM LLP, 28 State
Street, Suite 700, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF

(57) Abstract: The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

WO 2024/259132 A1